Literature DB >> 8152332

Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons.

H H Liou1, C R Wang, H C Chou, V L Arvanov, R C Chen, Y C Chang, C Y Chuang, C Y Chen, M C Tsai.   

Abstract

The effects of circulating anticardiolipin (ACL) antisera in lupus patients on the LP5 central neuron of snail were studied. Both GABA and glutamate increased a chloride conductance of the LP5 neuron. The ACL antisera decreased the GABA-elicited responses in a concentration dependent manner while it had no effect on glutamate-elicited responses. The ACL antisera affected neither the resting membrane current, nor the membrane conductivity of neuron. Antisera without the activity of anticardiolipin did not decrease the GABA-elicited responses. The seizure incidence of the patients with higher ACL antisera levels is also higher. It is concluded that ACL antisera inhibited the GABA ionophore receptor complex in a snail central neuron.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152332     DOI: 10.1016/0024-3205(94)00422-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  A swell in the armamentarium of antiepileptic drug targets.

Authors:  Karthik Rajasekaran; Howard Parker Goodkin
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

2.  Delayed catastrophic antiphospholipid syndrome after massive cerebral infarction.

Authors:  Wei Hsi Chen; Hung Sheng Lin; Yi Fen Kao; Jia Shou Liu
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 3.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

4.  Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

Authors:  R M Andrade; G S Alarcón; L A González; M Fernández; M Apte; L M Vilá; G McGwin; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

Review 5.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

6.  Antiphospholipid antibody, head-shaking and ataxia: an evidence of non-vascular neurotoxicity and successful treatment by plasmapheresis.

Authors:  Wei-Hsi Chen; Chung-Jen Chen
Journal:  Rheumatol Int       Date:  2008-11-29       Impact factor: 2.631

Review 7.  Causes of CNS inflammation and potential targets for anticonvulsants.

Authors:  Mercé Falip; Xavier Salas-Puig; Carlos Cara
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

8.  Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke.

Authors:  Jozélio Freire de Carvalho; Sandra Gofinet Pasoto; Simone Appenzeller
Journal:  Clin Dev Immunol       Date:  2012-03-25

9.  Neuropsychiatric Systemic Lupus Erythematosus: A Diagnostic Conundrum.

Authors:  Vivek Joseph; Rahul Anil; Sary Aristy
Journal:  J Clin Med Res       Date:  2016-08-30

Review 10.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.